My Photo
Blog powered by TypePad

Powered by Rollyo

Press Conference on IPR Protection 2007 Held in Beijing

On May 8, 2008 a press release from the International Sports Movement was available at Sports Features Communications.  The following is excerpted from that release:

Beijing Intellectual Property Working Conference and the Information Office of the Municipal Government jointly held a press conference on IPR protection 2007 at the Beijing Olympics Press Center.

Principals from the municipal IP Office, Press and Publication Administration, Administration for Industry and Commerce, High People’s Court, Customs and Cultural Enforcement Team presented at the annual event. 

By employing multiple tools in policies, government guidance and coordination, the municipality elevated the public’s awareness of IPR, fine-tuned its administration system and upgraded its promotion and protection standard, vaulting IPR protection in the nation’s capital to another height. 

Intellectual property filing activity across the board registered another record high year in 2007.  Patent applications exceeded 30,000 for the first time, racing to 31,680, up 19.3%.  Invention applications mounted to 18,763 (59.2% of all patent applications), ranking No.1 in the nation.  Trademark applications reached 51,383 while 14,893 trademarks were registered.  There were 295 newly added citywide effective famous marks, 99 marks with the title Beijing famous brand, 61 with China famous brand and 57 with China well-known marks. In terms of copyright, 110,573 works registered voluntarily and 3,334 software works registered, both ranking No.1 in the nation.  Copyright registrations were also proceeded for medal design, ticketing service label, torch design and torch relay slogan of the Beijing 2008 Olympics as well as icons of the Paralympics. 

The press conference is the fifth time the municipal government releases complete information of its IPR protection efforts to the public in the city.

Read the full release here.

Trade Agency Wants to End Deals Delaying Generics

The following is excerpted from a May 6, 2008 Reuters article by Diane Bartz:

A practice by major pharmaceutical companies of paying generic drug companies to delay putting cheaper medicines on the market violates federal law and must be stopped, a top ranking official with the U.S. Federal Trade Commission (FTC) said.

These so-called reverse payments are made after a generic company files with the Food and Drug Administration (FDA) to sell a generic version of a drug still under patent.

The maker of the original drug often sues for patent infringement, but sometimes these lawsuits are settled when the maker of the brand name drug gives the generic company money to bring the generic drug to market before the patent expires but much later than the generic company had wanted, a government source explained.

The settlements can be structured to make it appear that the drug companies are paying for something other than delayed generic entrance, according to the government source and an industry legal source, both of whom asked not to be identified because they are not authorized to speak to reporters.

Another pharmaceutical industry source, who asked not to be named, confirmed that reverse payments would often be structured so that it would look like the brand-name drug maker was paying for something else. "It's never: 'Here's $50 million, don't launch the product,"' the source said. "I don't think there's a place for those reverse payments."

The FTC says such payments violate antitrust law by dividing up the market.

Generics can be 20 percent to 90 percent cheaper than brand-name drugs.

All drug companies are required to report any patent settlement to the FTC.

Read the full article here.

Chinese Firms Triumph in U.S. Battery Suit

The following China Daily item appeared in the May 6, 2008 issue of China View:

A U.S. court's decision to shoot down the patent infringement claims of a U.S. battery maker has ended a lengthy case against Chinese battery manufacturers and marks the first victory of Chinese enterprises in trade disputes such as this.

"It lasted five years and cost millions of dollars," the China Battery Industry Association said in a press release yesterday, "but the victory marks a perfect ending."      

Experts said the win will put Chinese battery enterprises in a better position to tap overseas markets, the United States in particular, which have seen an annual twofold increase in recent years.

According to Wang Jingzhong, spokesman for the association, battery from China costs only half that of the local ones in the US.

Energizer Holdings, the second largest battery maker in the U.S., in 2003 filed complaints against more than 20 companies, including nine Chinese manufacturers, claiming they had infringed on Eveready's zero-mercury-added patent.

According to an announcement by Hogan & Hartson, the law firm that helped Chinese enterprises with the case, the patent claims were unfounded.

The U.S. Court of Federal Appeals for the Federal Circuit in late April affirmed a previous ruling by the US International Trade Commission (ITC) that Energizer's claim was not valid. It is the final decision on the case since this was the second time Energizer appealed.

Energizer used to ask Chinese manufacturers for $1 million as patent fees plus 2 to 3 cents on each battery sold. "That was unacceptable since we earn only 1 cent on each battery," said Wang from the association.

Read the full article here.

Intellectual Property Statistics

Each year the Intellectual Property Group at FTI researches and compiles statistics on intellectual property prosecution and litigation. They recently completed updating their statistics charts to include data for 2006.

The charts include:

  • Top Patent Damage Awards: 1980 - 2006 (The Polaroid v. Eastman Kodak case that I worked on for three years still remains at #1 at over $800 million.)

Top five from the list are:

  1. Polaroid v. Eastman Kodak ($873,158,971)
  2. Michelson v. Medtronic Sofamor Danek ($529,000,000)
  3. Eolas Technologies v. Microsoft ($521,000,000)
  4. City of Hope Medical v. Genentech ($500,100,000)
  5. Johnson & Johnson v. Guidant ($425,000,000)
  • Top Patent Damage Awards: 2006
  • Significant Patent Damage Settlements: 1980 - 2006
  • Significant Awards and Settlements - Copyrights/Trademarks/Trade Secrets: 1990 - 2006
  • Patent Cases Commenced in U.S. District Courts: FY1997 - FY2006

See the complete set of statistics here.

Evaluating Patent Investments

The Intellectual Property Prospector and the Beard Group Law and Business Publishers are hosting an audio briefing for identifying and evaluating patent investments on May 15, 2008.

David S. Ruder, Managing Director of Terrier IP Investments LLC and instructor for this briefing, will show you:

    * How patent assets are incorporated into investment strategies, including:
       - Equity investing (fundamental and event)
       - Opportunistic arbitrage (licensing and litigation)
       - Securitization deals
    * Current approaches to patent analytics
    * Today’s top trends and challenges in patent licensing and litigation
    * Investments in patent litigation
    * Impact of recent Supreme Court rulings and potential patent reforms
    * Insights for patent-rich companies seeking capital

David S. Ruder is Managing Director of Terrier IP Investments LLC, an investment advisory firm focused on intellectual property. His expertise is in building businesses based on intellectual property assets. David’s multi-disciplinary background includes experience as an intellectual property lawyer at Kirkland and Ellis, an investment banker with Dean Witter Reynolds, and one of the original team members of Ocean Tomo's mergers and acquisitions practice.

David is the author of the new book, “Strategies for Investing in Intellectual Property” published by the Beard Group and available as part of the special discounted Audio Conference/Book Learning Package. The book has been lauded as “an essential tool for understanding the range of IP investment strategies and how companies can unlock value and profit from them.”

Learn more and register here.

Sidley Announces Settlement of Patent Infringement Claims Against Fourth LED Manufacturer

The following is excerpted from Sidley Austin's May 6, 2008 press release:

Sidley Austin LLP announced today that firm client Professor Gertrude Neumark Rothschild has settled her patent infringement claims against Epistar Corporation, a Taiwanese corporation. The terms of the settlement are undisclosed. The Sidley team consisted of James D. Zirin and Ashe Puri, partner and associate respectively. Peter Toren of Kasowitz, Benson, Torres & Friedman LLP served as co-counsel. Professor Neumark had previously settled patent infringement claims against Toyoda Gosei, a Japanese entity, Osram, a German corporation, and against Philips Lumileds this past May for an undisclosed settlement.

Professor Neumark had alleged that Epistar had infringed U.S. Patent No. 4,904,618, “Process for Doping Crystals of Wide Band Gap Semiconductors,” and U.S. Patent No. 5,252,499, “Wide Band-Gap Semiconductors Having Low Bipolar Resistivity and Method of Formation” through the unauthorized manufacture, importation, use, sale and/or offer for sale of light emitting diodes (“LEDs”) and laser diode created using the processes described and claimed in each of these patents.

Despite the recognized potential of LEDs, their commercial use was initially limited because it was not commercially feasible to produce LEDs in blue, green and other high spectral ranges. Through the process claimed in Professor Neumark’s patents, it has become commercially feasible to produce such LEDs, and they have increasingly gained general acceptance as a superior lighting source.

Read the full press release here.

The Increasing Role of Antitrust Principles in Defining Patent Rights

The Antitrust, Pharmaceutical, and Standards Committees of the Intellectual Property Owners Association is hosting the above titled conference on June 9, 2008 in Washington, DC at the Ronald Regan Building and International Trade Center.

This conference will examine the role of competition law by the courts and antitrust enforcement agencies in defining patent rights. Panels will discuss a variety of industries and topics dealing with this ever-challenging intersection of patent and antitrust law.

Licensing IP in the Current Patent Litigation Environment will address the topic of licensing patents in light of the Supreme Court’s decision in MedImmune v. Genentech affecting declaratory relief jurisdiction and in Quanta v. LG Electronics addressing restrictive licensing practices.

Antitrust Implications of Standards Organization IP Policies will address principles of competition as they are applied to the standard setting activities. Such forums have been recognized as simultaneously having both procompetitive and anticompetitive potential, making differentiating between the two difficult – a situation only intensified by the increasing prevalence of IP rights that are incorporated into a standard. The panel will discuss the Federal Trade Commission’s activities in this arena, including the N-Data Solutions and Rambus cases.

Antitrust Liability in Reverse Payments Cases and Lifecycle Management in the Pharmaceutical Industry will focus on recent developments in the pharmaceutical industry and in particular the treatment of “reverse payments” under Hatch-Waxman life-cycle management and orange book listing strategies.

Inequitable Conduct, Walker Process and Handgards Litigation will address the status of inequitable conduct and fraud at the U.S. Patent and Trademark Office and related issues that arise later in a large number of patent infringement cases. Topics will include a review of recent case law; differences between fraudulent procurement in Walker Process and simple inequitable conduct claims following the Federal Circuit’s Dippin’ Dots decision; evolving perspectives on the Noerr-Pennington doctrine; and the problems of market definition and market power in antitrust counterclaims.

More information and registration are available here.

U.S. Patent Commissioner Speaks: Current Developments in Patents

Matthew J. Prinn, Business Development Manager for K&L Gates, extends an invitation to all subscribers and readers of Philip Brooks' Patent Infringement Updates to participate in a May 13, 2008 Webinar.

Luncheon Speaker: John J. Doll, U.S. Commissioner for Patents

U.S. patent law and practice is in its most dynamic period in recent memory.  The landscape of patent laws and regulations is being modified by the Courts, Congress and the USPTO. Recent changes in case law, the Patent Reform Act of 2007, and proposed rules changes combine to make this a unique and challenging time for patent stakeholders.

Hear the U.S. Commissioner for Patents, John Doll, comment on current developments in patents, most especially those occurring at the U. S. Patent and Trademark Office, and participate in questions and answers.

Moderator: Stephen C. Glazier, K&L Gates, Washington, D.C. office

Registration is complimentary; however, virtual seating is limited, so please register as soon as possible using this link.

DCGI Rules Out Low-Cost Version of Patented Drugs

Joe C Mathew, writing today, May 1, 2008, for the Business Standard, India’s leading business daily states:

The Drugs Controller General of India (DCGI) has decided to reject applications seeking marketing approvals for copycat versions of medicines that have product patents in the country.

The move is important as it allows multinational drug firms to launch their patent-protected medicines without fear of infringement by domestic drug-makers.

Leading drug firm Cipla recently launched a low-cost version of cancer drug erlotinib, challenging the patent enjoyed by Swiss drug firm Roche on the medicine in India.

The matter is currently under litigation after Roche dragged Cipla to the Delhi High Court alleging "patent infringement". DCGI's latest move will prevent a repeat of such cases as the authority will not give marketing approval for low-cost version of patented medicines.

Multinational drug firms have welcomed the DCGI move while domestic players have termed it "unwarranted" saying it doesn't have any legal basis. The law governing drug regulation (Drugs and Cosmetics Act, 1940) does not provide for any linkage between patent status and regulatory approvals, they say.

"Patent linkage is the practice that creates a link between the patent status of a product and the application for a marketing authorisation. It prevents registration and authorisation of generic medicines until the expiry of the patent and considerably delays generic market entry," says D G Shah, secretary general, Indian Pharmaceutical Alliance, the representative body of leading Indian drug makers.

Read the full article here.

Apple's Success Brings More Patent Lawsuits

Appearing in the April 28, 2008 issue of EE Times, Thomas Claburn of InformationWeek writes:

Apple's rise in sales has been accompanied by an increase in patent infringement lawsuits.
During the first four months of 2008, Apple was named as a defendant in eight patent infringement lawsuits, up from five during the same period in 2007. Only one such lawsuit was filed during the first four months of 2006, on behalf of Burst.com. Apple settled that lawsuit for $10 million last November. The first four months of 2005 also brought just one patent lawsuit against Apple. In 2004, three patent lawsuits were filed against Apple from January through the end of April.

In the latest such suit, Apple last week was sued for alleged patent infringement in the U.S. District Court of the Eastern District of Michigan.

The lawsuit, filed on behalf of inventor Henry Milan by Detroit-based law firm Butzel Long, claims that Apple's iPod Nano and iPod Touch use Flash memory in a way that violates U.S. patent No. 6,991,483.

The lawsuit seeks treble damages for willful infringement and an injunction against the sale of the iPod Nano and iPod Touch. However, Huget said the inclusion of that request in the initial filing didn't mean he would ultimately seek an injunction. It's not yet clear whether the case is strong enough to make an injunction against any of Apple's products a realistic possibility.

See the full release here.

Court Denies Hologic Request for Preliminary Injunction Against Sales of Contura

SenoRx, Inc. (Nasdaq:SENO) today [April 29, 2008] announced that a request for a preliminary injunction, filed by Hologic and its wholly-owned subsidiaries, Cytyc Corporation and Cytyc LP in their pending patent infringement suit against SenoRx, Inc., was denied by the United States District Court for the Northern District of California. The Court ordered the parties to schedule a trial within 60-90 days.

See full press release here.

AAAU Reference Center

The American Arbitration Association has developed guides, Frequently Asked Questions (FAQ) documents, and reports to help enhance users' knowledge of alternative dispute resolution in general, and about its application in particular areas or industries.

The suitability of arbitration as a prompt and effective means of resolving Intellectual Property (IP) disputes has been well recognized in recent years, and the AAA provides useful information to help raise clients' awareness and address questions.  The following is a list of these IP-related publications:

  • ALTERNATIVE DISPUTE RESOLUTION FOR COPYRIGHT AND TRADEMARK MATTERS
  • INTELLECTUAL PROPERTY WHITE PAPER
  • RESOLVING INTELLECTUAL PROPERTY DISPUTES OUT OF COURT
  • Patent Litigation: A Radically Changed Environment for Licensors and Licensees

Access the publications here (registration required).

Former Thomson Scientific Executive Appointed to PatentCafe Top Sales Spot

The following is excerpted from a PatentCafe April 24, 2008 press release I received via email (the Company's website does not yet have the full release available):

PatentCafe.com, Inc. is pleased to announce the appointment of David M. Schab as Vice President of Sales. As the latest member of PatentCafe’s executive team, David will assume responsibility for building the company’s global sales operations, and for introducing an expanded line of enterprise level patent portfolio management solutions.

PatentCafe’s artificial intelligence based solutions provide decision-support data for intellectual property managers responsible for corporate Open Innovation initiatives. The company’s line of IP software solutions are used for patent research, infringement analysis, product R&D strategy, licensing revenue development, patent-based business intelligence, portfolio management, and technology investment.

David joins PatentCafe from Hoover’s (a Dunn & Bradstreet Company), where he was National Director of Sales.

Previously, with Thomson Scientific, he was the Director of Global Sales and Client Services for Thomson’s patent information companies (Dephion, Derwent, Micropatent, Aureka, IIS). At Thomson, David designed and executed the company-wide organizational model that resulted in the doubling of the average monthly business production.

Read the full press release here.

CAT Patent Infringement Suits Could Spread to Others in Prepaid

An April 2008 featured article by Paybefore (an industry resource for prepaid and stored value cards) staff states, in part:

Chicago-based Card Activation Technologies, Inc. (CAT) is suing major retailers, including Barnes & Noble, Aeropostale, OfficeMax, TJX Companies, Sears and Walgreen Co. for infringement of its patent related to gift card activation and processing.

While the company’s focus is squarely on retailers, for now, lead counsel Mark D. Roth, of Orum & Roth LLC, tells Paybefore that there are other potential infringers, such as banks, processors and even terminal manufacturers that CAT could pursue in the future.

The full article is available to subscribers here.

CAT stated the following in an April 23, 2008 press release:

The Card Activation patent relates to a method used by most retailers for processing debit styled cards, which include gift cards and phone cards. Card Activation currently has lawsuits pending against Walgreen Company (NYSE:WAG), Sears Holding Corporation (Nasdaq:SHLD), TJX Companies (NYSE:TJX) and OfficeMax ((NYSE:OMX), as well as Barnes & Noble and Aeropastale. Card Activation has also placed on notice approximately 600 retailers relating to their potential infringement of the patent.

GUEST BLOG: In re Bilski Roll Call

By Charles R. Macedo, Amster Rothstein & Ebenstein LLP, cmacedo@arelaw.com[i]

On May 8, 2008, the Federal Circuit will be hearing oral argument in the In re Bilski case on the issue of what is a patent-eligible process.   There have been over twenty amici curiae briefs submitted.  These “friends of the Court” are from a wide range of industries and professions, including the financial services and sales sector, the computer and software sector, the biotechnology and pharmaceuticals sector, as well as legal and other associations and academics. 

In today’s IP Law 360, we have published a Roll Call and Score Card of the amici briefs (Download docs1396650v1bilski_roll_call.DOC).  A copy will also be available at our firm website: www.arelaw.com/articles/index.html.   We provide here a Roll Call of the amici parties sorted by industry with links to their amici briefs (where available):

Financial Services and Sales Sector

Since the Bilski claim at issue is directed to a financial service product (i.e., a method of managing risk), the industry that most obviously is directly interested in the outcome of this case is the financial service and sales sector.  In this regard, there are five submissions from the financial services and sales sector, including the submissions by: Reserve Management Corporation, PCT Capital LLC, Rearden Capital Corp. and Sales Optimization Group (“Reserve et al”), American Express Company (“AmEx”), Regulatory DataCorp, Inc. (“RDC”), CFPH, Inc. (“CFPH”), Financial Services Industry (“FSI”), and Pacific Life Insurance Company, The Hartford Financial Services Group, Inc., and John Hancock Life Insurance Company (U.S.A.) (not available).  (The author is principal attorney on Reserve et al submission).

Computer Software and Hardware Sector

A number of the questions posed by the Federal Circuit are directed to issues impacting the patentability of computer software and hardware, e.g., whether an process needs to be tied to a machine or needs to transform matter in order to be patent-eligible (Question 4).  There are seven briefs submitted by corporations in the software and computer sector, including the submissions by Accenture (“Accenture”), Koninklijke Philips Electronics N.V. (“Philips”), SAP America, Inc. (“SAP”), Yahoo! Inc. and Professor Robert P. Merges (“Yahoo!”), Dell, Inc., Microsoft Corporation, and Symantec Corporation (“Dell/Microsoft/Symantec”), International Business Machines Corporation (“IBM”), and Red Hat, Inc. (“Red Hat“).

Biotechnology and Pharmaceutical Sector

Much of the debate challenging the State Street “useful, concrete and tangible result” test for patent-eligible subject matter centers around comments made by Justice Breyer in his dissent from the dismissal of a petition for certiorari in Lab Corp. of Am. Holdings v Metabolite Labs., Inc., 126 S. Ct. 2921, 2928 (2006) (Breyer, J. dissenting), where he questioned the applicability of that test to pre-Diehr decisions by the Supreme Court.  The Lab Corp. case involved a claim directed to a method of diagnosing a disease.  In that petition, several members of the financial service sector weighed in on the debate because it appeared that the Supreme Court may address the State Street test.  Thus, it is perhaps not surprising that the biotechnology and pharmaceutical sector has in turn weighed in on Bilski.  In particular, to present two diametrically opposing views, briefs were submitted by the Biotechnology Industry Organization (“BIO”) (arguing in favor of a broad view of patent-eligible processes), and Eli Lilly and Company and The Association of American Medical Colleges (“Eli Lilly”) (arguing for a narrow view of patent-eligible processes).        

Associations 

A dozen different industry and law associations submitted amici briefs to the Federal Circuit in Bilski, including the American Intellectual Property Law Association (“AIPLA”), the Boston Patent Law Association (“BPLA“), the Federal Circuit Bar Association (“FCBA “), the Houston Intellectual Property Law Association (“HIPLA”), the Business Software Alliance (“BSA”), the Washington State Patent Law Association (“WSPLA“), the Intellectual Property Owners Association (“IPO”), the American Institute of Certified Public Accountants (“AICPA “), the Computer & Communications Industry Association (“CCIA”), the Software & Information Industry Association (“SIIA“), the Federation International Des Conseils En Propriete Industrielle (“FICPI”), the Consumers Union, the Electronic Frontier Foundation, and the Public Knowledge  (“CU/EFF/PK”), the American Civil Liberties Union (“ACLU”), and End Software Patents (“ESP”).   Significantly, the patent law associations generally favor a broader scope of patent-eligible subject matter, while the non-patent lawyer associations seek a narrower scope of patent-eligible subject matter or in some cases, simply propose rules that would eliminate patent protection. 

Academic

Perhaps because of the academic nature of the questions being posed --e.g., what should be the scope of patent-eligible processes -- a large number of academics have also weighed in with their own amici curiae submissions.  These briefs include both collective and individual briefs by academics, including:  22 Law and Business Professors (“22 Prof.”), Roberta J. Morris, Esq., Ph.D. (“Morris”), Jason V. Morgan (“Morgan”), Gregory Aharonian (“Aharonian”), Professor Robert P. Merges  (see Yahoo!), Professor John Duffy (see RDC), 10 Law Professors (“10 Prof.”), Professor Lee A. Hollaar (“Hollar”), Professor Kevin Emerson Collins (“Collins“), William Mitchell College of Law Intellectual Property Institute (“WMC”).


[i] Charles R. Macedo is a Partner at Amster, Rothstein & Ebenstein, LLP.  His practices specializes on intellectual property issues including litigating patent, trademark and other intellectual property disputes, prosecuting patents before the U.S. Patent and Trademark Office, and other patent offices throughout the world, registering trademarks and service marks with U.S. Patent and Trademark Office, and other trademark offices throughout the world, and drafting and negotiating intellectual property agreements.  He may be reached at cmacedo@arelaw.com.  This article is not intended to express the views of the firm or its clients.  Mr. Macedo was principal attorney on the amici curiae brief submitted on behalf of Reserve Management Corporation, PCT Capital LLC, Rearden Capital Corp. and Sales Optimization Group in In re Bilski.

Rambus Defeats FTC

A reader provided the following press release issued today, April 22, 2008, by The Voluntary Trade Council, Inc.:

The Federal Trade Commission's long-running prosecution of Rambus Inc. [NASDAQ:RMBS] suffered a critical defeat today after a three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit unanimously vacated the agency's 2007 decision against the company and ordered a new trial to address "serious concerns about the sufficiency of the evidence" in the case.

In a 24-page opinion authored by Senior Circuit Judge Stephen F. Williams, the D.C. Circuit said the FTC "failed to sustain its allegation of monopolization" based on Rambus' alleged deception before a computer memory standard-setting organization. The Court declined to extend Section 2 of the Sherman Antitrust Act to include "deceit merely enabling a monopolist to charge higher prices than it otherwise could have charged." Furthermore, the Court expressed doubt that the FTC had proved Rambus engaged in any deceptive conduct at all.

Skip Oliva, president of the Voluntary Trade Council, filed a brief with the D.C. Circuit supporting Rambus. He said today, "The D.C. Circuit made the right decision. The FTC attempted to expand its own power without any basis in existing antitrust doctrine--and without any credible evidence of wrongdoing by Rambus--and the court of appeals appropriately restrained the illegal actions of an unprincipled executive branch agency."

The D.C. Circuit's decision does not immediately end the Rambus litigation. The court's order merely returns the case to the FTC for possible retrial under the ground rule set by the court's opinion. The FTC could try to reinstate its original decision, however, through an appeal to the full D.C. Circuit or to the U.S. Supreme Court. The FTC could also decline to retry the case and dismiss its 2002 administrative complaint against the company.

Justin Muchoney Gets Dream Job

Justin Congratulations! 
Justin Muchoney
2008 Disney Parks Chief Magic Official

After months of grueling campaigning culminating in a two-day climax of in-Park competitions, Justin Muchoney claims the victory as the Disney Parks Chief Magic Official! Be sure to come back in May to find out the latest on Justin's CMO activities. Meanwhile you can still check out the videos of the CMO competitions at Walt Disney World© Resort.

Watch a replay of this morning's winner announcement live webcast.

e-Discovery Special Masters

Chere Estrin, CEO of Estrin LegalEd and owner of The Estrin Report blog, wrote on February 11, 2008:

I'm telling you, when a field pops, it really pops.  Apparently, the increased use of electronic discovery has resulted in a new set of practitioners: e-discovery special masters.

According to The Daily Record, a special master is an officer of the court appointed to help with its proceedings, and may perform functions such as taking testimony or advising the court as a neutral expert.

Essentially, you represent the judge and the court as an independent in evaluating technological disputes and electronic discovery issues,” explained Peter S. Vogel, chair of the Electronic Discovery and Document Retention Team and co-chair of the Internet and Computer Technology Practice Group at Gardere Wynne Sewell in Dallas.

Vogel, a partner at the firm, has worked on more than 20 cases with some form of an e-discovery special master. The role varies, explained Judge Shira Scheindlin, a U.S. District Court judge in the Southern District of New York and the author of several seminal opinions on e-discovery, including Zubulake v. UBS Warburg LLC, 229 F.R.D. 422 (S.D.N.Y. 2004).

Read the full post here.

Collecting Evidence of Infringement

In a presentation to the Boston Entrepreneurs' Network on January 3, 2006, Brian T. Moriarty of Hamilton, Brook, Smith & Reynolds, P.C. made the following observations about patent infringement investigations:

Collecting Evidence of Infringement

• Hunches and “I know it” DON’T work
• Go get proof
• Document your search
• Keep your lawyer in the loop and keep it confidential

Market Intelligence

• Web sites
• Patent applications
• Trade shows
• Trade journals
• Sales material
• Other lawsuits
• Word-of-mouth

Collecting Evidence

• Must be honest
• No illegal collecting of evidence
• No spying or fraud
• Can be aggressive, can’t be dishonest
• Everything you do will be second guessed

Analyze the Evidence

• Critically analyze evidence
• With valid scientific tests and methods
• Compare evidence with claims
• MAKE A CLAIM CHART

Develop Your Proof

• Can your theory of infringement be clearly explained?
• If not, something is wrong
• Every element must be included

See the full presentation here.

Flip Video Camera Maker Hit with Patent Infringement Lawsuit

Dawn Kawamoto posted the following today, April 17, 2008, at CNET's News Blog:

Advanced Video Technologies lobbed a patent infringement lawsuit against Pure Digital Technology, maker of the popular Flip Video cameras, according to a Reuters report.

The lawsuit, filed Wednesday in a U.S. District Court in New York, alleges Pure Digital infringed on Advanced Video's patent for its Full Duplex Single Chip Video Codec. The technology is designed to compress the video and allow it to be displayed on small-screen devices.

Advanced is seeking unspecified damages and a "reasonable" royalty, according to a Reuters interview with Stephen Roth, attorney for Advanced Video. He noted Advance is not seeking to halt sales of the Flip Video cameras.

Pure Digital is aware of the lawsuit, a representative for the company said, adding: "The suit is without merit and we will defend it vigorously."

Link to the article is available at nobosh.